BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/27/2026 8:10:55 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-02-14 03:02 |
|
Peer-Review Started |
|
2026-02-14 03:03 |
|
First Decision by Editorial Office Director |
|
2026-02-26 07:31 |
|
Return for Revision |
|
2026-02-26 07:31 |
|
Revised |
|
2026-03-10 01:15 |
|
Publication Fee Transferred |
|
2026-03-26 19:00 |
|
Second Decision by Editor |
|
2026-04-15 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-15 08:23 |
|
Articles in Press |
|
2026-04-15 08:23 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-14 01:11 |
|
Publish the Manuscript Online |
|
2026-05-27 08:10 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Abigail Layton Ellington, Danielle Rambuss, Sarah Barbina and Maithili Chitnavis |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abigail Layton Ellington, MD, Internal Medicine, Atrium Health Wake Forest Baptist, 1 Medical Center Blvd, Winston-Salem, NC 27157, United States. abigail.ellington@advocatehealth.org |
| Key Words |
Upadacitinib; Janus kinase 1 inhibitor; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Dose intensification; Secondary loss of response; Real-world evidence; Treatment durability; Corticosteroid reduction |
| Core Tip |
Real-world data guiding dose re-escalation of upadacitinib in inflammatory bowel disease (IBD) are limited. In this single-center cohort, off-label intensification in patients with secondary loss of response was associated with significant symptomatic improvement and reduced corticosteroid exposure, with favorable trends in objective measures. Most patients remained on the escalated dose at follow-up. No new laboratory safety signals were observed. These findings suggest dose intensification may represent a pragmatic management strategy in selected patients with IBD. |
| Publish Date |
2026-05-27 08:10 |
| Citation |
Ellington AL, Rambuss D, Barbina S, Chitnavis M. Clinical outcomes of upadacitinib dose escalation in inflammatory bowel disease: A single-center retrospective cohort study. World J Gastrointest Pharmacol Ther 2026; 17(2): 120059 |
| URL |
https://www.wjgnet.com/2150-5349/full/v17/i2/120059.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v17.i2.120059 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
